^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:spartalizumab (PDR001) (PD1 inhibitor) +
    naporafenib (ERAS-254) (BRAF inhibitor, pan-RAF inhibitor, cRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Eur J Cancer
    Title:

    First-in-Human Study of Naporafenib (LXH254) With or Without Spartalizumab in Adult Patients With Advanced Solid Tumors Harboring MAPK Signaling Pathway Alterations

    Published date:
    11/20/2023
    Excerpt:
    A total of 142 patients were included in the naporafenib dose-escalation (n=87), naporafenib/spartalizumab dose-escalation (n=12) and naporafenib/spartalizumab dose-expansion (n=43) arms...Two partial responses (PRs) occurred in naporafenib escalation, and 1 complete response and 3 PRs in the naporafenib/spartalizumab NRAS-mutated melanoma and KRAS-mutated NSCLC arms, respectively.
    DOI:
    10.1016/j.ejca.2023.113458
    Trial ID:
    NCT02607813